Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 7 min ago
Peer-reviewedCC BY-NC-ND 4.0Journal of Translational Medicine

Tailoring nanoplatforms for depression applications

  • Xiaoyan Li1
  • Shilin Wen1,2
  • Keer Zhang1
  • Sirun Lu1
  • Ge Gao1
  • Siyu Dai1
  • Minmin Jiang1,3
  • Jianer Chen2
  • Xiao-Ling Xu1,3
  1. 1Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China
  2. 2The Third Clinical Medical College, Zhejiang Chinese Medical University, 548 Binwen Road, Hangzhou, 310053 PR China
  3. 3Shulan International Medical College, Zhejiang Shuren University, 8 Shuren Street, Hangzhou, 310015 China
Read full textDOICite

Abstract

Background: Depression is a common psychiatric disorder associated with high recurrence rates and a substantial global disease burden. Although conventional antidepressant therapies remain the main treatment option, their clinical efficacy is often limited by delayed onset, inadequate brain targeting, systemic adverse effects, and considerable interindividual variability. These limitations highlight the need for more efficient drug delivery strategies for the central nervous system.

Main body: Nanomedicine has emerged as a promising approach to improve antidepressant delivery and therapeutic efficacy. Nanocarriers can enhance drug solubility and stability, prolong systemic circulation, and facilitate transport across the blood–brain barrier (BBB), thereby increasing drug accumulation in the brain. Recent advances in nanotechnology-based drug delivery systems, including lipid-based nanocarriers and polymeric nanoparticles, have demonstrated potential for controlled drug release and targeted brain delivery while modulating key pathological processes involved in depression.

Conclusion: Overall, nanomedicine represents a promising strategy for improving the precision and effectiveness of antidepressant therapy, although further studies are required to address challenges related to biosafety, large-scale production, and clinical translation.

Graphical Abstract:

Related

  1. Functionalized metal-organic frameworks as smart nanoplatforms: advancing tumor precision therapy through post-synthetic surface tailoring, challenges, and prospects for clinical translation.
    Shiva Velayati, Masoumeh Zahmatkeshan, Fariba Esmaeili +8
    Journal of nanobiotechnologyPeer-reviewedCC BYFull text1 citedInorganic & organometallic chemistryEurope PMCDOAJ
  2. Advances in Polydopamine-Based Nanoplatforms: Antioxidant Mechanisms and Applications in Oxidative Stress-Mediated Diseases
    Zhilin Wang, Zhu Liu, Luming Song +6
    Nano-Micro LettersPeer-reviewedCC BYFull text12 citedMaterials & polymersOpenAlex
  3. Spray pyrolysis derived Ce-doped SnO2 nanoparticles-based thin films: Tailoring band gap and conductivity for energy and optoelectronic applications
    Ghassan E. Alkinani, Abdul Rasool J. Katae, Mohammed Rasheed
    Experimental and Theoretical NANOTECHNOLOGYPeer-reviewedLicence not stated16 citedMaterials & polymersOpenAlex
  4. Tailoring the Structural, Optical, and Electrical Performance of PVA Through Sn0.8Mn0.2S Nanostructures Incorporation for Optoelectronic Applications
    Mohammed G. Althobaiti
    PolymersPeer-reviewedCC BY 4.0Full textMaterials & polymersCrossrefEurope PMC
  5. Multifunctional Nanoplatforms for Endoplasmic Reticulum-Targeted Cancer Therapy
    Zhu You, Jing Du, Tianqi Zhang +6
    ACS NanoPeer-reviewedCC BY-NC-ND 4.0Full text2 citedMaterials & polymersHAL

Cite

BibTeXRIS
BibTeX
@article{li2026tailoring,
  title = {{Tailoring nanoplatforms for depression applications}},
  author = {Xiaoyan Li and Shilin Wen and Keer Zhang and Sirun Lu and Ge Gao and Siyu Dai and Minmin Jiang and Jianer Chen and Xiao-Ling Xu},
  journal = {Journal of Translational Medicine},
  year = {2026},
  month = aug,
  doi = {10.1186/s12967-026-08811-w},
  url = {https://doi.org/10.1186/s12967-026-08811-w},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Tailoring nanoplatforms for depression applications
AU  - Xiaoyan Li
AU  - Shilin Wen
AU  - Keer Zhang
AU  - Sirun Lu
AU  - Ge Gao
AU  - Siyu Dai
AU  - Minmin Jiang
AU  - Jianer Chen
AU  - Xiao-Ling Xu
PY  - 2026
DA  - 2026/08/19
JO  - Journal of Translational Medicine
DO  - 10.1186/s12967-026-08811-w
UR  - https://doi.org/10.1186/s12967-026-08811-w
AB  - Background: Depression is a common psychiatric disorder associated with high recurrence rates and a substantial global disease burden. Although conventional antidepressant therapies remain the main treatment option, their clinical efficacy is often limited by delayed onset, inadequate brain targeting, systemic adverse effects, and considerable interindividual variability. These limitations highlight the need for more efficient drug delivery strategies for the central nervous system.  Main body: Nanomedicine has emerged as a promising approach to improve antidepressant delivery and therapeutic efficacy. Nanocarriers can enhance drug solubility and stability, prolong systemic circulation, and facilitate transport across the blood–brain barrier (BBB), thereby increasing drug accumulation in the brain. Recent advances in nanotechnology-based drug delivery systems, including lipid-based nanocarriers and polymeric nanoparticles, have demonstrated potential for controlled drug release and targeted brain delivery while modulating key pathological processes involved in depression.  Conclusion: Overall, nanomedicine represents a promising strategy for improving the precision and effectiveness of antidepressant therapy, although further studies are required to address challenges related to biosafety, large-scale production, and clinical translation.  Graphical Abstract:
SN  - 1479-5876
ER  -